Chronic graft-versus-host disease (GVHD) in children.
Chronic graft-versus-host disease (GVHD) in children.
复制标题
DOI：
10.1016/j.pcl.2009.11.003
复制
发表时间：
2010-02
影响因子：
2.6
通讯作者：
Schultz, Kirk R.
中科院分区：
文献类型：
--
作者：
Baird, Kristin;Cooke, Kenneth;Schultz, Kirk R.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative approach for many pediatric diseases. According to the most recent analysis from the Center of International Blood and Marrow Transplant Research (CIBMTR) data, approximately 4,500 allo-HSCTs are performed each year in children less than 20 years of age [1]. The majority of children are transplanted for malignancy, however increasing numbers receive an allo-HSCT for nonmalignant diseases such as bone marrow failure, immunodeficiency and certain metabolic syndromes/disorders [2-7]. Concurrent with increasing indications for allo-HSCT, there has been a surge of interest in immune modulation to harness the graft versus tumor (GVT) effects when this procedure is used for hematologic malignancies. These factors along with improvements in the safety of allo-HSCT have led to an expanding population of long-term survivors, many of whom suffer from long-term toxicities, including chronic graft versus host disease (cGVHD).
登录
查看更多内容
影响因子：
4.3
作者：
Arora, Mukta;Nagaraj, Sriharsha;Weisdof, Daniel J.
通讯作者：
Weisdof, Daniel J.
影响因子：
2.1
作者：
Baker, K. Scott;Fraser, Christopher J.
通讯作者：
Fraser, Christopher J.
影响因子：
1.7
作者：
Beredjiklian, PK;Drummond, DS;August, C
通讯作者：
August, C
影响因子：
6.2
作者：
Au, WY;Lo, CM;Kwong, YL
通讯作者：
Kwong, YL
影响因子：
20.3
作者：
Bunin, N;Carston, M;King, R
通讯作者：
King, R